$-0.50 EPS Expected for XOMA Corporation (XOMA)

February 15, 2018 - By Adrian Erickson

 $ 0.50 EPS Expected for XOMA Corporation (XOMA)

Analysts expect XOMA Corporation (NASDAQ:XOMA) to report $-0.50 EPS on March, 15.They anticipate $2.39 EPS change or 82.70 % from last quarter’s $-2.89 EPS. After having $1.98 EPS previously, XOMA Corporation’s analysts see -125.25 % EPS growth. The stock decreased 2.96% or $0.81 during the last trading session, reaching $26.6. About 187,751 shares traded or 2.35% up from the average. XOMA Corporation (NASDAQ:XOMA) has declined 51.66% since February 15, 2017 and is downtrending. It has underperformed by 68.36% the S&P500.

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

Among 7 analysts covering Xoma Limited (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Xoma Limited had 22 analyst reports since July 23, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, November 14 report. The firm has “Neutral” rating given on Wednesday, July 22 by Ladenburg Thalmann. As per Monday, November 14, the company rating was downgraded by Wedbush. On Tuesday, September 5 the stock rating was upgraded by Wedbush to “Outperform”. The stock of XOMA Corporation (NASDAQ:XOMA) has “Buy” rating given on Wednesday, August 5 by Wedbush. Wedbush maintained XOMA Corporation (NASDAQ:XOMA) rating on Tuesday, February 6. Wedbush has “Buy” rating and $33.0 target. Jefferies downgraded the stock to “Hold” rating in Thursday, July 23 report. As per Tuesday, December 19, the company rating was maintained by Wedbush. The rating was reinitiated by H.C. Wainwright on Tuesday, October 17 with “Buy”. As per Monday, March 27, the company rating was maintained by Wedbush.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $216.63 million. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It currently has negative earnings. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

More notable recent XOMA Corporation (NASDAQ:XOMA) news were published by: Globenewswire.com which released: “XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference” on September 11, 2017, also Globenewswire.com with their article: “XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.” published on December 07, 2017, Globenewswire.com published: “XOMA Earns $3 Million Milestone Payment from its License Agreement with …” on September 11, 2017. More interesting news about XOMA Corporation (NASDAQ:XOMA) were released by: Globenewswire.com and their article: “XOMA Strengthens Leadership Team with Appointments of Chief Business Officer …” published on January 08, 2018 as well as Seekingalpha.com‘s news article titled: “XOMA: Another Ligand In The Making?” with publication date: July 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.